JP2023522029A5 - - Google Patents

Info

Publication number
JP2023522029A5
JP2023522029A5 JP2022562645A JP2022562645A JP2023522029A5 JP 2023522029 A5 JP2023522029 A5 JP 2023522029A5 JP 2022562645 A JP2022562645 A JP 2022562645A JP 2022562645 A JP2022562645 A JP 2022562645A JP 2023522029 A5 JP2023522029 A5 JP 2023522029A5
Authority
JP
Japan
Prior art keywords
igg
molecule
modified
modified igg
canid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522029A (ja
JP7879810B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027836 external-priority patent/WO2021212081A1/en
Publication of JP2023522029A publication Critical patent/JP2023522029A/ja
Publication of JP2023522029A5 publication Critical patent/JP2023522029A5/ja
Priority to JP2026035921A priority Critical patent/JP2026097964A/ja
Application granted granted Critical
Publication of JP7879810B2 publication Critical patent/JP7879810B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562645A 2020-04-17 2021-04-16 イヌ科動物抗体バリアント Active JP7879810B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026035921A JP2026097964A (ja) 2020-04-17 2026-03-06 イヌ科動物抗体バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17
US63/011,453 2020-04-17
PCT/US2021/027836 WO2021212081A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026035921A Division JP2026097964A (ja) 2020-04-17 2026-03-06 イヌ科動物抗体バリアント

Publications (3)

Publication Number Publication Date
JP2023522029A JP2023522029A (ja) 2023-05-26
JP2023522029A5 true JP2023522029A5 (cg-RX-API-DMAC10.html) 2024-04-19
JP7879810B2 JP7879810B2 (ja) 2026-06-24

Family

ID=75888187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562645A Active JP7879810B2 (ja) 2020-04-17 2021-04-16 イヌ科動物抗体バリアント
JP2026035921A Pending JP2026097964A (ja) 2020-04-17 2026-03-06 イヌ科動物抗体バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026035921A Pending JP2026097964A (ja) 2020-04-17 2026-03-06 イヌ科動物抗体バリアント

Country Status (17)

Country Link
US (2) US20230242635A1 (cg-RX-API-DMAC10.html)
EP (1) EP4136106A1 (cg-RX-API-DMAC10.html)
JP (2) JP7879810B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230005156A (cg-RX-API-DMAC10.html)
CN (1) CN115996949A (cg-RX-API-DMAC10.html)
AU (1) AU2021256056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022020944A2 (cg-RX-API-DMAC10.html)
CA (1) CA3175921A1 (cg-RX-API-DMAC10.html)
CL (2) CL2022002857A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014695A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22080846A (cg-RX-API-DMAC10.html)
IL (1) IL297287A (cg-RX-API-DMAC10.html)
MX (1) MX2022012866A (cg-RX-API-DMAC10.html)
PE (1) PE20230108A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552742A1 (cg-RX-API-DMAC10.html)
TW (1) TW202204403A (cg-RX-API-DMAC10.html)
WO (1) WO2021212081A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗il31抗体
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
AU2023289332A1 (en) * 2022-06-21 2024-12-12 Zoetis Services Llc Canine antibody mutants
US20240254231A1 (en) 2023-01-20 2024-08-01 PetMedix Ltd. Therapeutic antibodies
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
JP5833145B2 (ja) * 2011-02-04 2015-12-16 ゾエティス・エルエルシー 免疫原性bordetellabronchiseptica組成物
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CN116271014A (zh) * 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
KR20220066002A (ko) * 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
MX2023008785A (es) * 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.

Similar Documents

Publication Publication Date Title
JP2023522030A5 (cg-RX-API-DMAC10.html)
JP2023543262A5 (cg-RX-API-DMAC10.html)
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
EP2170960B1 (en) Single-domain antigen-binding proteins that bind mammalian igg
JP7189142B2 (ja) 抗ヒトアネキシンa1抗体
US9284347B2 (en) Chromatographic method for purifying FC-containing proteins
JP2022513025A5 (cg-RX-API-DMAC10.html)
US20060159695A1 (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2021047559A1 (zh) 一种断裂型内含肽、使用其的重组多肽的制备方法
CN104428317A (zh) 修饰的抗体区及其用途
JP2024505072A5 (cg-RX-API-DMAC10.html)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2023542737A5 (cg-RX-API-DMAC10.html)
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
WO2021174594A1 (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2024531346A5 (cg-RX-API-DMAC10.html)
JP2023550628A5 (cg-RX-API-DMAC10.html)
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
JP2019514343A5 (cg-RX-API-DMAC10.html)
JP2024500354A (ja) ヘテロ二量体化のための直交変異
US20240174734A1 (en) Parvovirus antibody
JP2024515301A5 (cg-RX-API-DMAC10.html)
JP2024534118A (ja) 抗her2抗体及びその使用方法
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE